GelStat Corporation Adds Retailers, Updates Web Site
Brooks Pharmacy and Longs Drug Stores Added to Growing List of Retailers
Carrying GelStat Migraine
MINNEAPOLIS, July 28 /PRNewswire-FirstCall/ -- GelStat Corporation (OTC:GSAC)
(BULLETIN BOARD: GSAC) today announced that GelStat Migraine is now available
at Brooks Pharmacy and in all Longs Drug Stores located in the continental
United States.
Brooks Pharmacy is a chain of more than 330 pharmacies located throughout New
England and New York and has been a well-recognized name in the New England
pharmacy industry for more than 65 years. Brooks Pharmacy is operated by a
wholly-owned subsidiary of The Jean Coutu Group, which recently announced the
acquisition of approximately 1,539 Eckerd drugstores. Once completed, The Jean
Coutu Group will become the fourth largest drugstore chain in North America,
with a combined network of 2,196 stores.
Longs Drug Stores is one of the most recognized retail drug store chains on the
West Coast with more than 470 stores in California, Hawaii, Washington, Nevada,
Colorado and Oregon.
"We are very pleased with the addition of these two outstanding retailers to
our growing distribution network," said Stephen Roberts, M.D., chairman and
chief executive officer of GelStat. "We continue to receive positive feedback
and additional re-orders from retailers who have only recently stocked GelStat
Migraine. With good visibility over the next several months, we are confident
of adding yet more leading national and regional chains before year-end." The Company also announced that it has updated its web site to provide
information on retailers and major drug wholesalers presently offering GelStat
Migraine to their customers. The updated portion of the GelStat site can be
viewed at http://www.gelstat.com/purchase.asp .
About GelStat Migraine GelStat Migraine is a new, non-prescription medication for acute relief from
the pain and associated symptoms of migraine and migraine-like headaches. Over
90 percent of those with migraine use OTC headache pain relievers, largely
accounting for domestic sales of over 560 million units per year. In only about
25 percent of those with moderate to severe headache pain are these older
medications reported to exhibit any effect.
A recent clinical trial showed GelStat Migraine to be effective in 83 percent
of patients, whose migraine pain was either eliminated or arrested at the mild
pain phase by early treatment.
About GelStat Corporation GelStat Corporation is a consumer healthcare company dedicated to the
cost-effective development and marketing of advanced OTC healthcare products. Development efforts are focused on large markets where GelStat products can
offer improved efficacy, safety, and/or convenience over existing OTCs. The
Company's initial efforts center on developing products for migraine therapy
and to improve sleep, both multi-billion dollar global markets.
For more information, visit http://www.gelstat.com/ .
Forward-Looking Statements
This press release contains "forward-looking" statements within the meaning of
the Private Securities Litigation Reform Act of 1995. Any statement other than
a statement of historical fact should be considered a forward- looking
statement. Such forward-looking statements are based on the Company's current
expectations and involve known and unknown risks, uncertainties, or other
factors which may cause actual results, performance or achievements of the
Company to be materially different from any future results, performance or
achievements expressed or implied by such forward-looking statements. Risks,
uncertainties and assumptions include the possibility that the market for the
sale of certain products, or all products, may not develop as expected, or at
all. Readers are cautioned not to place undue reliance on those forward-
looking statements, which speak only as of the date hereof. The company
undertakes no obligation and does not intend to release publicly any revisions
to these forward-looking statements to reflect events or circumstances after
the date hereof or to reflect unanticipated events or developments. DATASOURCE: GelStat Corporation CONTACT: Media, Tony Carideo of The Carideo Group, Inc., +1-612-317-2880, or Investor Relations, Brock Malky of Insight Capital, +1-724-453-1800, both for GelStat Corporation Web site: http://www.gelstat.com/purchase.asp http://www.gelstat.com/
|